While anti-ANGPT2 treatment did not alter the density of CD8+ T cells in either the tumor periphery or the tumor core at 18 weeks, it significantly enhanced the infiltration of CD8+ T cells into both these areas by 20 weeks (Supplemental Figure 9, A and B). This evidence concerns the gene CD8A and neoplasm.